TEMOZOLOMIDE (SCH52365) IN PATIENTS W/ ANAPLASTIC ASTROCYTOMA AT FIRST RELAPSE

替莫唑胺 (SCH52365) 用于首次复发的间变性星形细胞瘤患者

• 批准号: 6244603
• 负责人: HARRY S GREENBERG
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244603
• 关键词: antineoplastics; clinical research; drug adverse effect; drug screening /evaluation; glioblastoma multiforme; human mortality; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; quality of life

This is a phase II study of temozolomide (SCH 52365) in the treatment of patients with anaplastic astrocytoma at first relapse. The efficacy will be measured as progression free survival rate at six months. Secondary measures efficacy will be quality of life and survival. Toxicity will be carefully monitored.

这是替莫唑胺 (SCH 52365) 治疗的 II 期研究 间变性星形细胞瘤患者首次复发的比例。 功效 将测量六个月时的无进展生存率。 次要衡量疗效的指标是生活质量和生存率。 将仔细监测毒性。